Document Detail


Safety of regadenoson in patients with end-stage liver disease.
MedLine Citation:
PMID:  20848256     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Regadenoson is a selective A(2A) receptor agonist that is used for vasodilator stress myocardial perfusion imaging (MPI). Since the drug is partially metabolized by the liver, its safety in patients with end-stage liver disease (ESLD) needs to be determined.
METHODS AND RESULTS: We studied 168 consecutive patients with ESLD who had regadenoson stress gated single photon emission computed tomography MPI between January 2008 and March 2010 before planned orthotopic liver transplantation and compared the hemodynamic responses and safety profile to 168 control patients. There were 72 women (43%) in ESLD versus 87 (52%) in the control group (P = .1). The patients with ESLD were younger (58 ± 7 vs 62 ± 12 years, P = .0002), but more likely to be Caucasians (P = .002). The MPI images were normal in 161 patients (96%) in each group. The left ventricular ejection fraction was 72 ± 10% in ESLD and 66 ± 11% in the control patients (P = .0001). The heart rate increase in response to regadenoson was lower in patients with ESLD than in the control group (16 ± 11 vs 23 ± 16 bpm, P = .0001), but the changes in systolic and diastolic blood pressures were similar (-9 ± 12 vs -11 ± 14 mmHg and -6 ± 8 vs -7 ± 10 mmHg, respectively, P = NS). There were no deaths or medication-related adverse events that required hospitalization in either group within 30 days of the study.
CONCLUSION: This is the first study to document the tolerability and safety profile of regadenoson in patients with ESLD.
Authors:
Wael Aljaroudi; Fahad Iqbal; Jayanth Koneru; Pradeep Bhambhvani; Jaekyeong Heo; Ami E Iskandrian
Related Documents :
710856 - Significance of microscopic cholangitis in alcoholic liver disease.
8568966 - Focal sparing of liver parenchyma in steatosis: role of the gallbladder and its vessels.
12084556 - Clinical spectrum of acute sporadic hepatitis e and possible benefit of glycyrrhizin th...
3116106 - Leprosy, liver and jaundice.
6965646 - The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspir...
21982316 - Prospective validation of the prognostic usefulness of b-type natriuretic peptide in as...
Publication Detail:
Type:  Journal Article     Date:  2010-09-18
Journal Detail:
Title:  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology     Volume:  18     ISSN:  1532-6551     ISO Abbreviation:  J Nucl Cardiol     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423534     Medline TA:  J Nucl Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  90-5     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, J1-5, Cleveland, 44195, OH, USA, aljarow@ccf.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Unusual intrathoracic activity of Tc-99m sestamibi in a patient with chest pains.
Next Document:  Knowledge and attitudes regarding colorectal cancer screening among medical students: a tale of two ...